LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
LB Pharmaceuticals Inc (LBRX)
Company Research
Source: GlobeNewswire
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs. Throughout his career, Dr. Rawls has led or contributed to more than a dozen successful regulatory filings and product approvals in the United States, Europe, and Japan, with specific experience in neuropsychiatric diseases. “Dr. Rawls has a remarkable depth of regulatory expertise that will be instrumental as we advance LB-102 into a Phase 3 clinical trial in schizophrenia and a Phase 2 clinical trial in bipolar depression in 2026,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. “His experience leading successful FDA and global regulatory engagements, particularly in neuropsychiatry, will be invaluable as we continue to execute on our work to make LB-102 the first benzamide antipsychotic drug approved for neuropsychiatric disorders in t
Show less
Read more
Impact Snapshot
Event Time:
LBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBRX alerts
High impacting LB Pharmaceuticals Inc news events
Weekly update
A roundup of the hottest topics
LBRX
News
- LB Pharmaceuticals (NASDAQ:LBRX) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e)" rating on the stock.MarketBeat
- LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
LBRX
Sec Filings
- 11/18/25 - Form 3
- 11/13/25 - Form 8-K
- 11/12/25 - Form 8-K
- LBRX's page on the SEC website